文献速递胸部肿瘤放疗放疗物理与技术

3'-脱氧-3'-(18F)氟胸苷正电子发射断层显像/计算机断层显像在立体定向体部放疗非小细胞肺癌中的研究:一项先导研究

3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study.
PubMed 文献 · Adv Radiat Oncol · 2022-07-26

该先导研究比较了立体定向体部放疗(SBRT)前三组患者(SBRT前、SBRT后稳定肺纤维化、SBRT后可疑或证实局部复发)的FLT-PET/CT摄取,并比较呼吸门控与非门控FLT-PET扫描。结果显示纤维化组SUVpeak、SUVmean、SUVmax显著低于复发组和治疗前组,呼吸门控与非门控扫描SUV变量相关性好(r=0.8-1.0)。作者认为FLT-PET/CT可能有助于鉴别SBRT相关纤维化与复发,推荐报告SUVmax和SUV95的非门控FLT-PET/CT。

要点

  • 纤维化组SUVpeak、SUVmean、SUVmax显著低于复发组和治疗前组。
  • 复发组SUV50和SUV95与治疗前组统计学相似。
  • 呼吸门控与非门控FLT-PET的SUV变量相关性好(r=0.8-1.0)。

核心结论

  • FLT-PET/CT可能有助于鉴别SBRT相关纤维化与复发。
  • 推荐报告SUVmax和SUV95值的非门控FLT-PET/CT。

研究设计与样本

  • 该研究为单机构先导研究,计划每队列20例、共60例,实际招募41例(队列1为20例,队列2为16例,队列3为5例),于2015年至2019年入组。
  • 研究对象为在该机构计划或已接受SBRT、影像学显示纤维化或复发的早期非小细胞肺癌患者。
  • 所有患者均接受FLT-PET/CT检查:队列1在SBRT前,队列2和队列3分别在纤维化或复发时。
  • 采用Kruskal-Wallis检验比较3个队列的FLT-PET SUV变量(包括SUVmax、SUVmean、SUVpeak、SUV50和SUV95),采用Spearman相关系数分析呼吸门控与非门控FLT-PET SUV变量的相关性。

主要发现

  • 41例患者中,大多数诊断为I期肺癌(86%),最常见的处方为48 Gy分4次(59%)。
  • 35例患者进行了呼吸门控FLT-PET。
  • 呼吸门控与非门控扫描的FLT SUV变量相关性好(r=0.8-1.0)。
  • 纤维化组的SUVpeak、SUVmean和SUVmax显著低于复发组和治疗前组。
  • 复发组的SUV50和SUV95值与治疗前组统计学相似。

临床怎么用

  • 作者认为FLT-PET/CT可能有助于鉴别SBRT相关纤维化与复发。
  • 作者推荐报告SUVmax和SUV95值的非门控FLT-PET/CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The primary objective was to compare 3'-deoxy-3'-(18F) fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) uptake in 3 cohorts of stereotactic body radiation therapy (SBRT) patients: (1) pre-SBRT, (2) stable post-SBRT lung fibrosis, and (3) suspicious or proven local recurrence post-SBRT. The secondary objectives were to optimize FLT-PET imaging by comparing FLT uptake in respiratory-gated (4-dimensional) versus nongated (3-dimensional) FLT-PET scans. METHODS: Patients with early-stage non-small cell lung cancer planned or treated with SBRT at the institution with radiographic findings of fibrosis or recurrence were eligible for the study. All patients underwent imaging with FLT-PET/CT before SBRT in cohort 1 and at fibrosis or recurrence in cohort 2 and 3, respectively. The planned sample size was 20 patients in each cohort, with 60 patients total. FLT-PET standardized uptake value (SUV) variables including SUVmax, SUVmean, SUVpeak, SUV50, and SUV95 were compared among the 3 cohorts using the Kruskal-Wallis test. The correlation of respiratory-gated and nongated FLT-PET SUV variables was performed using the Spearman correlation coefficient. RESULTS: Forty-one patients were recruited for the study (20 in cohort 1, 16 in cohort 2, and 5 in cohort 3) between 2015 and 2019. The majority received a diagnosis of stage I lung cancer (86%), and the most common prescription was 48 Gy in 4 fractions (59%). Respiratory-gated FLT-PET was performed in 35 patients. The FLT SUV variables were well correlated between respiratory-gated and nongated scans (r = 0.8-1.0). The SUVpeak, SUVmean, and SUVmax were significantly lower in the fibrosis cohort compared with the recurrence and pretreatment cohorts. The SUV50 and SUV95 values in the recurrence cohort were statistically similar to the pretreatment cohort. CONCLUSIONS: FLT-PET/CT may be helpful in differentiating SBRT-related fibrosis from recurrence. Nongated FLT-PET/CT with reporting of SUVmax and SUV95 values is recommended.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lewis S, Chan M, Weiss J, et al. 3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study. Adv Radiat Oncol. 2022. PMID: 36420186. doi:10.1016/j.adro.2022.101037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。